EMMANUEL ENOKPA: Open Payments
NPI 1063539500 · GERMANTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$702 in 36 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $702
Food & beverage: $702
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 8 | $118 |
| Novo Nordisk Inc | 4 | $99 |
| Sumitomo Pharma America, Inc. | 4 | $88 |
| Corcept Therapeutics | 2 | $69 |
| AstraZeneca Pharmaceuticals LP | 4 | $64 |
| Astellas Pharma US Inc | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| PFIZER INC. | 2 | $32 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Organogenesis Inc. | 1 | $30 |
Products named: GEMTESA, MOUNJARO, Korlym, BREZTRI, Wegovy, JARDIANCE, Veozah, Rybelsus.
Industry payments across MD — which companies pay providers there.
